Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl

Details Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl

1978-01-04

1980-02-12

Brown, Johnnie R.

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated via claimed linking group, bond, chelating agent,...

536 26, A61K 3170

Patent

active

041883780

ABSTRACT:
A method of utilizing 9-.beta.-D-arabinofuranosyl-2-fluoroadenine, known as 2-F-AraA (NSC 118218), in the treatment of murine leukemia and as an antiviral agent for DNA viruses, such as DNA viruses Herpes Simplex Virus Type I and Vaccinia virus grown in H.Ep-2 cells in culture. An operable dosage for utilization of 2-F-AraA is a treatment span of 1-10 days with the dosage 2-8 times per day at 8-400 mg/kg/dose. It has been further found that a single dosage on days 1, 5, and 9 based on a 10-day treatment schedule gave satisfactory results.

REFERENCES:
patent: 3501456 (1970-03-01), Shen et al.
patent: 4069382 (1978-01-01), Baker et al.
Brockman, R. W., et al., Biochem. Pharmacol. 26, 2193-2196, (1977).

Affiliated with

Also associated with

Rating

Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer and antiviral activity of 9-.beta.-D-arabinofuranosyl will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1854862